Wir sind mit live! Mehr erfahren

CRISPR Therapeutics

CRSP

Börsenwert 4,76 Mrd. $

49,25 USD

-2,27

4,41 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

49,28

+0,03

0,06 %

1 Tag

-4,41 %

5 Tage

-6,92 %

1 Monat

-5,67 %

3 Monate

1,4 %

6 Monate

-11,61 %

Seit Jahresbeginn

-8,41 %

1 Jahr

-28,03 %

5 Jahre

-48,81 %

10 Jahre

249,54 %

Profil: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Mitarbeiter: 393

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 59,2 %

Neutral 30,6 %

Negativ 10,2 %

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Zacks Investment Research

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

The Motley Fool

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

Substantial revenue from its flagship drug Casgevy should be right around the corner. Investors can expect a pivotal update on CTX310 before the end of the year.

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026. Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial Session Type: Late-Breaking Science (Oral Presentation) Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction Session Date and Time: Monday, November 9, 2026, 8:00 a.m.

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Schaeffers Research

3 Trending Names Overtaking Wall Street Today

Wall Street is buzzing today thanks to an overdue reprieve from bond yields.

3 Trending Names Overtaking Wall Street Today

Zacks Investment Research

Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt